proprotein convertase subtilisin/kexin type 9(English)
- inhibition is an effective strategy in reducing cardiovascular disease risk by lipid-lowering therapy with statins. Approved by the FDA for reducing low-density lipoprotein cholesterol in high-risk patients. Also as PCSK9
- LDL-R, AAV-PCSK9, CVD, EGF-A, FDA, LDL-C, PCSK, PCSK9
- Cardiology, Therapeutic approaches, Atherosclerosis /atherogenic
- https://doi.org…OMES.120.007521
- https://doi.org…acc.2022.05.041
- https://doi.org…NAHA.115.016080
- https://doi.org…NAHA.123.065213